Omics-based Biomarkers for the Early Alzheimer Disease Diagnosis and Reliable Therapeutic Targets Development

摘要

Background: Alzheimer’s disease (AD), the most common cause of dementia in adult-hood, has great medical, social, and economic impact worldwide. Available treatments result insymptomatic relief, and most of them are indicated from the early stages of the disease. Therefore,there is an increasing body of research developing accurate and early diagnoses, as well as disease-modifying therapies.Objective: Advancing the knowledge of AD physiopathological mechanisms, improving early diag-nosis and developing effective treatments from omics-based biomarkers.Methods: Studies using omics technologies to detect early AD, were reviewed with a particularfocus on the metabolites/lipids, micro-RNAs and proteins, which are identified as potential bio-markers in non-invasive samples.Results: This review summarizes recent research on metabolomics/lipidomics, epigenomics andproteomics, applied to early AD detection. Main research lines are the study of metabolites frompathways, such as lipid, amino acid and neurotransmitter metabolisms, cholesterol biosynthesis, andKrebs and urea cycles. In addition, some microRNAs and proteins (microglobulins, interleukins),related to a common network with amyloid precursor protein and tau, have been also identified aspotential biomarkers. Nevertheless, the reproducibility of results among studies is not good enoughand a standard methodological approach is needed in order to obtain accurate information.Conclusion: The assessment of metabolomic/lipidomic, epigenomic and proteomic changes associ-ated with AD to identify early biomarkers in non-invasive samples from well-defined participantsgroups will potentially allow the advancement in the early diagnosis and improvement of therapeu-tic interventions.